Adjuvant combo shows potential for universal influenza vaccine

Researchers at National Jewish Health have discovered how to prime a second arm of the immune system to potentially boost influenza vaccine effectiveness. A combination of two adjuvants, chemicals used to boost the effectiveness of some vaccines, induced CD8, or killer, T cells to join antibodies in response to influenza infection. Since the killer T cells targeted a highly conserved protein that does not change from year to year, the adjuvant strategy suggests potential for a universal flu vaccine.

“Most vaccines protect against disease by boosting antibody protection,” said lead author post-doctoral fellow Megan MacLeod, PhD. “We have shown that the two adjuvants work in concert to generate memory CD8 , which can kill infected cells. We believe that this strategy of stimulating both the cellular and humoral immune responses holds promise for better vaccines.”

Vaccines prepare the immune system to respond quickly to an infection with antibodies, Y-shaped molecules that neutralize or otherwise inactivate pathogens.

Aluminum salts, or alum, have been used for nearly a century as an adjuvant to boost the effectiveness of many vaccines. Surprisingly no one is sure even today exactly how it works. The only other adjuvant approved for use in the United States, monophosphoryl lipid A (MPL), is used by GlaxoSmithKline to boost the antibody response of some of its vaccines.

Dr. MacLeod, senior author Philippa Marrack, FRS, PhD, and their colleagues evaluated the responses of mice immunized with influenza vaccines containing no adjuvant, each adjuvant alone and both together. They engineered the so that any immune defense would be provided by killer T cells, not antibodies. Several weeks after the immunization, they infected the mice with influenza A virus.

They found that unvaccinated mice lost about 15 percent of their body weight in the first eight days after infection, then regained some of that weight by 20 days after infection. Mice whose vaccines contained either alum or MPL adjuvants lost less weight but did not fully regain their original weight. Mice whose vaccines contained both adjuvants together lost about 5 percent of their original weight and regained it all back rapidly.

The researchers also found that mice receiving vaccines with both adjuvants had the fewest viral particles in their lungs four days after infection.

Further experiments revealed that alum promoted long-lived CD8 memory cells, but that MPL was required to produce activated cells, ready and able to kill. The findings were published in the May 10, 2011, issue of the Proceedings of The National Academy of Sciences.

Current vaccines use antigens against two proteins on the viral surface, neuraminidase (N), and hemagglutinin (H), to which can bind. Because these cell-surface proteins mutate frequently, new vaccines must be formulated each year to recognize a viral strains.

Killer T cells instead recognize viral fragments displayed on the surface of infected cells. The researchers used as their vaccine a fragment from the viral nucleus, which rarely changes. This suggests the possible development of a universal that would not have to be reformulated and administered every year.

Provided by National Jewish Health

not rated yet
add to favorites email to friend print save as pdf

Related Stories

Research may lead to new and improved vaccines

Mar 14, 2011

Alum is an adjuvant (immune booster) used in many common vaccines, and Canadian researchers have now discovered how it works. The research by scientists from the University of Calgary's Faculty of Medicine ...

Small molecule with high impact

Mar 02, 2010

Researchers from the vaccinology and applied microbiology department at the Helmholtz Center for Infection Research in Braunschweig, Germany, have now found a new molecule with the capacity of improving responses to vaccines. ...

Recommended for you

FDA approves hard-to-abuse narcotic painkiller

7 hours ago

(HealthDay)—A new formulation of a powerful narcotic painkiller that discourages potential abusers from snorting or injecting the drug has been approved by the U.S. Food and Drug Administration.

Race affects opioid selection for cancer pain

7 hours ago

(HealthDay)—Racial disparities exist in the type of opioid prescribed for cancer pain, according to a study published online July 21 in the Journal of Clinical Oncology.

FDA approves tough-to-abuse formulation of oxycodone

8 hours ago

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe ...

Tough-to-abuse formulation of oxycodone approved

8 hours ago

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe pain when other ...

EU regulator: Morning-after pill OK for all women

Jul 24, 2014

(AP)—A commonly used morning-after pill is suitable for use by heavier women, the European Medicines Agency said Thursday after a review of the evidence sparked by the French manufacturer's declaration that the drugs didn't ...

Physicians warned about counterfeit medical devices

Jul 24, 2014

(HealthDay)—Physicians should be aware of the prevalence and serious consequences associated with use of counterfeit medical devices, according to a letter to the editor published online July 20 in Lasers in ...

User comments